Compositions comprising bile acid sequestrants for treating esophageal disorders
AssigneeIronwood Pharmaceuticals, Inc.
InventorMark G. CURRIE
Life of this patent
Estimating the term…
Abstract
Disclosed herein are novel compositions and methods for treating or preventing upper GI tract disorders and protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor, and optionally one or more agent chosen from antacids, histamine H2-receptor antagonists, γ-aminobutyricacid-b (GABA-B) agonists, prodrugs of GABA-B agonists, and protease inhibitors.
Claims9
1-122. (canceled)
A sustained-release pharmaceutical dosage form for oral administration to a subject in need thereof comprising an amount of at least one bile acid sequestrant that is in a range from 0.1 g to 1.0 g, wherein:
- the at least one bile acid sequestrant is selected from the group consisting of colesevelam, colesevelam hydrochloride, and combinations thereof, and a gastric-retention vehicle composition comprising one or more hydrogels;
- said dosage form expands upon contact with gastric fluid;
- characterized in that the dosage form is retained in a person's stomach for a period of three hours or more following ingestion;
- and
- the percentage of bile acid sequestrant is present in an amount from between 10% to about 75% of the total weight.
Dependencies are inferred from the claim text.